Editorial
doi: 10.1200/JCO.2008.20.6284.
Epub 2009 Mar 9.
When wishful thinking leads to a misty-eyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab
- PMID: 19273695
- DOI: 10.1200/JCO.2008.20.6284
Item in Clipboard
Editorial
When wishful thinking leads to a misty-eyed appraisal: the story of the adjuvant colon cancer trials with edrecolomab
J Clin Oncol.
.
No abstract available
Comment in
-
EpCAM as a target in cancer therapy.J Clin Oncol. 2010 May 20;28(15):e239-40; author reply e241-2. doi: 10.1200/JCO.2009.26.8540. Epub 2010 Apr 12. J Clin Oncol. 2010. PMID: 20385979 No abstract available.
Comment on
-
Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer.J Clin Oncol. 2009 Apr 20;27(12):1941-7. doi: 10.1200/JCO.2008.18.5710. Epub 2009 Mar 9. J Clin Oncol. 2009. PMID: 19273708 Clinical Trial.
Similar articles
-
Edrecolomab (Panorex) as adjuvant therapy for stage II colon cancer.Clin Colorectal Cancer. 2001 May;1(1):16-7. doi: 10.1016/S1533-0028(11)70532-1. Clin Colorectal Cancer. 2001. PMID: 12445374 No abstract available.
-
Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.Lancet. 2002 Aug 31;360(9334):671-7. doi: 10.1016/S0140-6736(02)09836-7. Lancet. 2002. PMID: 12241873 Clinical Trial.
-
Lessons learned from the edrecolomab story: how a checkered past became a checkered flag for monoclonal antibodies in colorectal cancer therapy.Onkologie. 2005 Jun;28(6-7):311-2. doi: 10.1159/000085570. Epub 2005 Jun 2. Onkologie. 2005. PMID: 15933417 No abstract available.
-
Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma.Crit Rev Oncol Hematol. 2001 Oct;40(1):17-24. doi: 10.1016/s1040-8428(01)00131-7. Crit Rev Oncol Hematol. 2001. PMID: 11578913 Review.
-
[Oncology 2010].Dtsch Med Wochenschr. 2010 Jun;135(25-26):1339-40. doi: 10.1055/s-0030-1255167. Epub 2010 Jun 16. Dtsch Med Wochenschr. 2010. PMID: 20556695 Review. German. No abstract available.
Cited by
-
Recent advances in targeted therapy of colorectal cancer: impacts of monoclonal antibodies nanoconjugates.Bioimpacts. 2019;9(3):123-127. doi: 10.15171/bi.2019.16. Epub 2019 Mar 8. Bioimpacts. 2019. PMID: 31508327 Free PMC article.
-
Identification, Culture and Targeting of Cancer Stem Cells.Life (Basel). 2022 Jan 27;12(2):184. doi: 10.3390/life12020184. Life (Basel). 2022. PMID: 35207472 Free PMC article. Review.
-
Nuclear Ep-ICD expression is a predictor of poor prognosis in "low risk" prostate adenocarcinomas.PLoS One. 2015 Feb 19;10(2):e0107586. doi: 10.1371/journal.pone.0107586. eCollection 2015. PLoS One. 2015. PMID: 25695234 Free PMC article.
-
EpCAM modulates NF-κB signaling and interleukin-8 expression in breast cancer.Mol Cancer Res. 2013 Apr;11(4):418-26. doi: 10.1158/1541-7786.MCR-12-0518. Epub 2013 Feb 1. Mol Cancer Res. 2013. PMID: 23378578 Free PMC article.
-
Nuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers.PLoS One. 2010 Nov 30;5(11):e14130. doi: 10.1371/journal.pone.0014130. PLoS One. 2010. PMID: 21152431 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
